Reliability of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure: HM-PRO

by Pushpendra Goswami, Esther N. Oliva, Tatyana Ionova, Roger Else, Jonathan Kell, Adele K. Fielding, Daniel M. Jennings, Marina Karakantza, Saad Al-Ismail, Graham P. Collins, Stewart McConnell, Catherine Langton, Magda J. Al-Obaidi, Metod Oblak, Sam Salek
Published 2020-10-01

Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Construct Validity Study

by Pushpendra Goswami, Esther N. Oliva, Tatyana Ionova, Roger Else, Jonathan Kell, Adele K. Fielding, Daniel M. Jennings, Marina Karakantza, Saad Al-Ismail, Graham P. Collins, Stewart McConnell, Catherine Langton, Magda J. Al-Obaidi, Metod Oblak, Sam Salek
Published 2020-09-01

Preclinical toxicology and safety pharmacology of the first-in-class GADD45β/MKK7 inhibitor and clinical candidate, DTP3

by Laura Tornatore, Daria Capece, Daniel D'Andrea, Federica Begalli, Daniela Verzella, Jason Bennett, Gary Acton, Elizabeth A. Campbell, James Kelly, Michael Tarbit, Nigel Adams, Selina Bannoo, Antonio Leonardi, Annamaria Sandomenico, Domenico Raimondo, Menotti Ruvo, Angela Chambery, Metod Oblak, Magda J. Al-Obaidi, Richard S. Kaczmarski, Ian Gabriel, Heather E. Oakervee, Martin F. Kaiser, Ashutosh Wechalekar, Reuben Benjamin, Jane F. Apperley, Holger W. Auner, Guido Franzoso
Published 2019-01-01